Drug Trial Radar · NCT00421928
Tapentadol (CG5503)
Last checked: Nov 19, 2026Latest source record: Apr 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,030
Actual
Start
Jan 2007
Primary completion
Jul 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Grünenthal GmbH
- First posted
- Jan 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the knee, in comparison with placebo and Oxycodone Controlled Release (CR).
Conditions
- Osteoarthritis, Knee
- Pain
Interventions
oxycodoneDrug
10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
placeboDrug
matching placebo twice a day (BID) during 15 weeks
tapentadol (CG5503)Drug
50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.Time frame: Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.